Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen
Authors
Keywords
Overall Survival, Tamoxifen, Therapeutic Drug Monitoring, Poor Metabolizer, Tamoxifen Treatment
Journal
CLINICAL PHARMACOKINETICS
Volume 54, Issue 8, Pages 797-810
Publisher
Springer Nature
Online
2015-05-04
DOI
10.1007/s40262-015-0273-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of cytochrome P450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis, metabolism, and response to endocrine therapy
- (2015) Heather L. Blackburn et al. CANCER CAUSES & CONTROL
- Clinical significance of CYLD downregulation in breast cancer
- (2014) Mitsuhiro Hayashi et al. BREAST CANCER RESEARCH AND TREATMENT
- Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen
- (2014) Rob ter Heine et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy
- (2014) Jessica Mwinyi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- CYP2D6 Genotype and Adjuvant Tamoxifen
- (2014) D A Berry CLINICAL PHARMACOLOGY & THERAPEUTICS
- Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies
- (2014) Matthew P. Goetz et al. JNCI-Journal of the National Cancer Institute
- CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy
- (2013) Wendy A. Teft et al. BREAST CANCER RESEARCH AND TREATMENT
- Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen
- (2013) Lisette Binkhorst et al. BREAST CANCER RESEARCH AND TREATMENT
- CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
- (2013) K. Beelen et al. BREAST CANCER RESEARCH AND TREATMENT
- CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
- (2013) M A Province et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- CYP2D6 Genotype and Tamoxifen Activity: Understanding Interstudy Variability in Methodological Quality
- (2013) M J Ratain et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Influence of CYP2D6 Polymorphisms on Serum Levels of Tamoxifen Metabolites in Spanish Women with Breast Cancer
- (2013) Mercedes Zafra-Ceres et al. International Journal of Medical Sciences
- CYP2D6 Genotyping and the Use of Tamoxifen in Breast Cancer
- (2013) D. Berry JNCI-Journal of the National Cancer Institute
- Relationship between Genotypes Sult1a2 and Cyp2d6 and Tamoxifen Metabolism in Breast Cancer Patients
- (2013) Ana Fernández-Santander et al. PLoS One
- Importance of highly selective LC–MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen
- (2012) N. G. L. Jager et al. BREAST CANCER RESEARCH AND TREATMENT
- CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8
- (2012) M. P. Goetz et al. CLINICAL CANCER RESEARCH
- CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
- (2012) James M. Rae et al. JNCI-Journal of the National Cancer Institute
- CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Meredith M. Regan et al. JNCI-Journal of the National Cancer Institute
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
- (2012) Christina Davies et al. LANCET
- Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?
- (2012) Karin Beelen et al. Nature Reviews Clinical Oncology
- Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients
- (2011) Kazuma Kiyotani et al. BREAST CANCER RESEARCH AND TREATMENT
- Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment
- (2011) In Hae Park et al. BREAST CANCER RESEARCH AND TREATMENT
- Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients
- (2011) Joanne S. L. Lim et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Increasing Tamoxifen Dose in Breast Cancer Patients Based on CYP2D6 Genotypes and Endoxifen Levels: Effect on Active Metabolite Isomers and the Antiestrogenic Activity Score
- (2011) M F Barginear et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma
- (2011) T E Mürdter et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
- (2011) L Madlensky et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study
- (2011) William J. Irvin et al. JOURNAL OF CLINICAL ONCOLOGY
- Association between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients with Tamoxifen Treatment
- (2011) Hyung Seok Park et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- CYP2D6 Inhibition and Breast Cancer Recurrence in a Population-Based Study in Denmark
- (2011) T. L. Lash et al. JNCI-Journal of the National Cancer Institute
- Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
- (2011) Meredith M Regan et al. LANCET ONCOLOGY
- SULT1A1,CYP2C19and disease-free survival in early breast cancer patients receiving tamoxifen
- (2011) Ann M Moyer et al. PHARMACOGENOMICS
- Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
- (2010) Jennifer Gjerde et al. BMC CANCER
- CYP2D6 Polymorphisms as Predictors of Outcome in Breast Cancer Patients Treated with Tamoxifen: Expanded Polymorphism Coverage Improves Risk Stratification
- (2010) W. Schroth et al. CLINICAL CANCER RESEARCH
- Impact ofCYP2D6*4genotype on progression free survival in tamoxifen breast cancer treatment
- (2010) Julia Carolin Stingl et al. CURRENT MEDICAL RESEARCH AND OPINION
- Significant Effect of Polymorphisms inCYP2D6andABCC2on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients
- (2010) Kazuma Kiyotani et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen
- (2009) Masatsugu Okishiro et al. CANCER
- Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
- (2009) Werner Schroth JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- No Association Between CYP2D6*10 Genotype and Survival of Node-negative Japanese Breast Cancer Patients Receiving Adjuvant Tamoxifen Treatment
- (2009) T. Toyama et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Genotype-guided tamoxifen therapy: time to pause for reflection?
- (2009) Timothy L Lash et al. LANCET ONCOLOGY
- Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment
- (2008) Y. Xu et al. ANNALS OF ONCOLOGY
- Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy
- (2008) Kazuma Kiyotani et al. CANCER SCIENCE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started